An official website of the United States government
NIOSH List of Hazardous Drugs in Healthcare Settings, 2024
December 2024
DHHS (NIOSH) Publication Number 2025-103
The NIOSH List of Hazardous Drugs in Healthcare Settings is a tool designed to assist healthcare workers and employers in identifying which drugs routinely handled by employees are considered by NIOSH to be hazardous drugs.
The NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 (NIOSH Pub No 2025—103) followed the guidelines in the Procedures for developing the NIOSH list of hazardous drugs in healthcare settings. It added 25 drugs to the 2016 List, 12 with manufacturer’s special handling information (MSHI), and removed 7 drugs from the 2016 List. The drugs reviewed for this update were either newly approved or received new safety-related warnings from the FDA between January 2014 and December 2015. Also added to the NIOSH 2024 List were recently approved drugs with MSHI through May 2023 that had been previously announced on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016 website.
The table below provides NIOSH updates made after the December 2024 publication of NIOSH List of Hazardous Drugs in Healthcare Settings, 2024.
July 17, 2025
Drugs approved by the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research that have manufacturer’s special handling information (MSHI) meet the NIOSH definition of a hazardous drug, see the NIOSH Procedures for developing the NIOSH list of hazardous drugs in healthcare settings. The manufacturers of datopotamab deruxtecan (Datroway®), treosulfan (Grafapex™), and telisotuzumab vedotin (Emrelis™) include MSHI in the package insert. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs. Table 1 includes drugs that have MSHI in the package insert. For additional information, see the package inserts for these drugs.
| Drug | Links | Date Updated | |
|---|---|---|---|
| datopotamab deruxtecan (Datroway®) | 10:00 – Antineoplastic Agents | 07/17/2025 | |
| treosulfan (Grafapex™) | 10:00 – Antineoplastic Agents | 07/17/2025 | |
| telisotuzumab vedotin (Emrelis™) | 10:00 – Antineoplastic Agents | 07/17/2025 |
Suggested Citation
NIOSH [2024]. NIOSH list of hazardous drugs in healthcare settings, 2024. By Ovesen JL, Sammons D, Connor TH, MacKenzie BA, DeBord DG, Trout DB, O’Callaghan JP, Whittaker C. Cincinnati, OH: U.S. Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2025-103 (Supersedes 2016-161),